Century Therapeutics

IPSC · NASDAQ

$1.64+$0.17 (+11.56%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.47

IPSC analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $5.22 (+218.4% upside)

Low: $2.02
Now: $1.64
High: $8.40

Upgrades and downgrades

The latest rating actions, newest first

IPSC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Mizuho	May 27, 2026	Initiates	Outperform	$8.00	40%
HC Wainwright & Co.	Apr 21, 2026	Maintains	Buy	$2.00 → $5.00	32%
Piper Sandler	Jan 20, 2026	Maintains	Overweight	$2.00 → $4.00	40%
Leerink Partners	Nov 17, 2025	Downgrade	Outperform → Market Perform	$7.00 → $2.00	38%

The case for and against

Updated Oct 31, 2025

Bull case

Century Therapeutics Inc demonstrates a strong potential for growth with its CNTY-101 product, which is projected to capture up to 15% of the market share by 2035, highlighting a promising revenue outlook in a competitive landscape. The company has made significant investments in developing in-house GMP manufacturing capabilities, which could enhance efficiency and reduce supply chain risks associated with producing its innovative cell therapies. Furthermore, its advanced platform employing iPSCs and CRISPR technology positions Century Therapeutics to outperform traditional cell therapy products, potentially resulting in improved therapeutic efficacy and broader market adoption.

Bear case

Century Therapeutics Inc. may face a negative outlook due to potential downward revisions in risk-adjusted projections and price targets, which have been highlighted multiple times in the provided excerpts. This indicates that the financial metrics and valuation assessments may be adversely affected by the company's performance and market conditions. As a biotechnology firm specializing in advanced cell therapy products, any challenges in product development, regulatory approval, or market acceptance could significantly impact its financial stability and future growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.